BUDGET IMPACT MODEL OF OMALIZUMAB IN THE TREATMENT OF CHRONIC SPONTANEOUS URTICARIA IN ITALY
Author(s)
Ravasio R1, Cawson MR2, McBride D2, Balp M3, Roccia A4
1Health Publishing & Services Srl, Milan, Italy, 2RTI Health Solutions, Manchester, UK, 3Novartis Pharma AG, Basel, Switzerland, 4Novartis Farma SpA, Origgio, Italy
OBJECTIVES: A 3-year budget-impact model (BIM) was developed to estimate the impact on the Italian health care budget of introducing omalizumab for the treatment of patients with chronic spontaneous urticaria (CSU) with inadequate response to H1-antihistamines (licensed dose). METHODS: The model considered patients with CSU aged ≥ RESULTS: The total number of patients treated in the first year was estimated to be 27,490, with 2,996 of those treated with omalizumab, increasing to a total of approximately 27,708 in the third year, with 7,925 receiving omalizumab. Considering only drug costs, the incremental budget impact of introducing omalizumab 300mg to the current market share was estimated to be €4.4 million in the first year, increasing to €11.7 million in the third year. Considering total direct medical costs, it was possible to show that part of the incremental drug costs of introducing omalizumab 300mg was offset by decrease in other resources: €1.4 million (total incremental budget) in the first year to €3.7 million in the third year. CONCLUSIONS: The use of omalizumab to treat CSU with inadequate response to H1-antihistamines increases drug and drug-related costs, but this is partially offset by reduced disease-related costs in omalizumab recipients.
Conference/Value in Health Info
2015-11, ISPOR Europe 2015, Milan, Italy
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PSS13
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Sensory System Disorders